Detected ·
Desentum Oy
€28M—
Finnish drug developer Desentum Oy has closed an oversubscribed €28M equity round, one of the largest ever raised by a privately held Finnish drug development company, to advance its genetically engineered allergen immunotherapy programmes for birch, peanut and cat allergies.
- Website
- —
- linkedin.com/company/5419925
- Amount
- €28 000 000 EUR
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-13 16:17:01 UTC
- Signal ID
- 8d999eb4-55b4-4119-87ab-942f5beb88ae
As the API returns it
{
"id": "8d999eb4-55b4-4119-87ab-942f5beb88ae",
"created_at": "2026-10-13T16:17:01.869298Z",
"company_name": "Desentum Oy",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/5419925",
"event_type": "funding",
"funding_amount": 28000000,
"funding_currency": "EUR",
"funding_stage": null,
"message": "*Finnish drug developer Desentum Oy has closed an oversubscribed €28M equity round, one of the largest ever raised by a privately held Finnish drug development company, to advance its genetically engineered allergen immunotherapy programmes for birch, peanut and cat allergies.*"
}